Speaking of being stuck in a rut…with guts. You’ve tried everything to lose weight—you eat healthy, exercise more, manage stress better and get enough sleep—but nothing seems to move the needle on the scale. Are you paying attention to your chemical exposure? Obesogens are endocrine disrupting chemicals (EDCs) that sabotage weight loss efforts by altering … Read more
brand newYou can now listen to Fox News articles! With millions of people using injectable GLP-1 drugs like Ozempic, Wegovy or Zepbound, many may wonder what happens if they stop. Previous clinical trials have suggested an encouraging “recovery” effect, where patients regain a significant portion of their lost weight immediately after treatment ends. However, a … Read more
Visit the News Center Even short interventions are associated with changes in the risk of heart attack, stroke, and death Sarah Moser and Alaska Adams/Washio Medicine WashU drug researchers have found that stopping GLP-1 drugs like semaglutide and terzepatide — even temporarily — increases the risk of heart attack, stroke and death compared to staying … Read more
Generally, when investors are looking for growth, they turn to industries like technology. Here, revenues may rise in double or even triple digits, leading to explosive stock performance. But in recent years, a unique area of the pharmaceutical market has presented such an opportunity. And it’s in the weight loss drug space. just now, Eli … Read more
Welcome to The Thin Line, a New York Post series on the dark side of GLP-1 drugs. Although GLP-1 agonists sold under brand names like Ozympic have helped millions of people lose weight, manage diabetes and improve other health conditions, they are not without risks. Check back for more stories about the lesser-known downsides of … Read more
The city’s chief financial officer, Ashley Groffenberger, sent a letter to the City Council on Monday saying that health insurance rates for city employees are increasing nearly 23 percent in the fiscal year that begins in July — the highest year-over-year premium costs the city has seen “in recent history.” According to the city, Boston … Read more
In the last two years Eli Lilly (NYSE: LLY ) It has established itself as a leader in the weight loss market. This is thanks to the company’s Terzapatide, a compound sold under the name Zipbound as an anti-obesity drug (and Monjaro in the treatment of diabetes) that became the world’s best-selling drug in 2025. … Read more
5 minutes of reading Tony Alvarado, 45, is a mathematics professor at Rice University from Houston, Texas, and has a history of heart problems. A combination of too little exercise, stress eating, and drinking contributed to weight gain that threatened his livelihood. Here’s how he put his act together through a comprehensive diet plan that … Read more
Simple measurements don’t always tell the whole story Lee Charlie/Shutterstock I consider myself a healthy person. I eat lots of fruits and vegetables, love fiber, eat rocket twice a week and try to sneak it in for lunch on the days I don’t have it. But when I recently calculated my body mass index (BMI), … Read more
In January, New Nordisk (NYSE: NVO ) Vigoi has broken new ground in the weight loss market by launching an oral version of its popular anti-obesity drug. It is the first oral GLP-1 approved for long-term weight management, and Novo Nordisk hopes it will help it regain market share in this area. While Oral Vigovi … Read more